UtroGen shares traded lower Wednesday after the ODAC of the Food and Drug Administration voted against the benefit/risk of UGN-102 (mitomycin) for intravesical solution.
What’s Going On With UroGen Pharma Stock Wednesday?
Where Today's News Shapes Tomorrow
